Abstract
Objective To study the clinical effects of the Tanreqing injection combined with Danshen-Chuanxiongqin injection for the patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and its effects on plasma NO and endothelin-1 (ET-1) levels. Methods A total of 79 patients with AECOPD in our hospital from May 2014 to January 2017 were enrolled in this study. The subjects were randomly divided into the control group (n=39) and the combined therapy group (n=40). The control group were treated with Tanreqing injection, the combined therapy group were treated with Tanreqing injection combined with Danshen-Chuanxiongqin injection. The two groups were treated for 10 days. The clinical effects of the two groups after treatment were compared. The MPAP, PASP, PADP, PaO2, PaCO2, SaO2, NO and ET-1 of the two groups before and after treatment were compared. Results The total efficacy rate of the combined therapy group was 97.5% (39/40), which was significantly higher than 82.1% (32/39) of the control group (χ2=5.178, P=0.023). After treatment, the MPAP (25.19 ± 8.71 mmHg vs. 35.28 ± 9.52 mmHg, t=4.917), PASP (44.35 ± 12.26 mmHg vs. 57.24 ± 11.17 mmHg, t=4.881), PADP (17.16 ± 4.05 mmHg vs. 26.40 ± 3.85 mmHg, t=10.38), PaCO2 (42.70 ± 6.31 mmHg vs. 51.44 ± 6.83 mmHg, t=5.910) of the combined therapy group were significantly lower than those of the control group (P<0.05). After treatment, the PaO2 (73.95 ± 7.82 mmHg vs. 67.21 ± 7.16 mmHg, t=3.993), SaO2 (94.86% ± 5.11% vs. 83.63% ± 4.27%, t=10.586) of the combined therapy group were significantly higher than those of the control group (P<0.05). After treatment, the plasma NO (55.82 ± 10.08 μmol/L vs. 46.34 ± 8.50 μmol/L, t=4.513) of the combined therapy groupwas significantly higher than the control group (P<0.05) and the plasma ET-1 (80.41 ± 8.95 ng/L vs. 87.68 ± 9.24 ng/L, t=3.552) of the combined therapy groupwere significantly lower than the control group (P<0.05). Conclusions The Tanreqing injection combined with Danshen-Chuanxiongqin injection showed good efficacy for the patients with AECOPD, and the therapy can reduce the pulmonary arterial hypertension and ET-1, improve the lung tissue oxygen supply and NO release, and improve the cardiopulmonary function. Key words: Pulmonary disease, chronic obstructive; Tanreqing injection; Danshen-Chuanxiongqin injection; Nitric oxide; Endothelin-1
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
